

Amendments to the Claims

- 1. (Original)** A method of examining schizophrenia, which comprises measuring concentration(s) of (a) D-serine, (b) L-serine or (c) D-serine and L-serine in a biological sample.
- 2. (Original)** The examination method of claim 1, wherein an index is that the D-serine concentration in a biological sample is lower than an average of said concentration in a healthy individual or a group of healthy individuals.
- 3. (Original)** The examination method of claim 1, wherein an index is that the D-serine concentration in a biological sample is lower than an average-standard deviation of the concentration in a healthy individual or a group of healthy individuals.
- 4. (Original)** The examination method of claim 1, wherein an index is that the D-serine concentration in a biological sample is lower than the average + standard deviation of said concentration in an individual with schizophrenia or a group of individuals with schizophrenia.
- 5. (Original)** The examination method of claim 1, wherein an index is that the L-serine concentration in a biological sample is higher than an average of said concentration in a healthy individual or a group of healthy individuals.
- 6. (Original)** The examination method of claim 1, wherein an index is a ratio of the D-serine concentration to the total serine concentration in a biological sample.
- 7. (Original)** The examination method of claim 6, wherein an index is that the ratio of the D-serine concentration to the total serine concentration in a biological sample is lower than an average of said ratio in a healthy individual or a group of healthy individuals.

8. (Original) The examination method of claim 6, wherein an index is that the ratio of the D-serine concentration to the total serine concentration in a biological sample is lower than an average-standard deviation of said ratio in a healthy individual or a group of healthy individuals.

9. (Currently amended) The examination method of claim 6, wherein an index is that the ratio of the D-serine concentration to the total serine concentration in a biological sample is lower than an ~~average+standard~~ average+standard deviation of said ratio in an individual with schizophrenia or a group of individuals with schizophrenia.

10. (Currently amended) The examination method of ~~any of claims 1 to 9~~ claim 1, further comprising selecting patients with schizophrenia for whom the D-serine therapy is effective.

11. (Currently amended) The examination method of ~~any of claims 1 to 10~~ claim 1, which uses an amino acid labeling reagent.

12. (Original) The examination method of claim 11, further comprising steps of contacting an amino acid labeling reagent with a biological sample to label serine and separating or quantifying the labeled D-serine and the labeled L-serine.

13. (Original) The examination method of claim 12, further comprising a step of separating and quantifying the labeled serine before the step of separating or quantifying the labeled D-serine and the labeled L-serine.

14-15. (Cancelled)

16. (Original) The examination method of claim 13, wherein the labeled serine is separated or quantified using chromatography.

17. (Cancelled)

18. (Currently amended) The examination method of claim ~~14, 15 or 17~~ 16, wherein the ~~column or capillary is a column or capillary for optical resolution~~ chromatography is high performance liquid chromatography.

19. (Currently amended) The examination method of claim ~~16 or 17~~ 12, wherein the ~~chromatography is high performance liquid chromatography~~ labeled D-serine and the labeled L-serine are separated or quantified using a column or capillary.

20. (Currently amended) The examination method of claim ~~17~~ 19, wherein the ~~chromatography is high performance liquid chromatography and the column or capillary is a column or capillary for optical resolution~~.

21. (Currently amended) The examination method of ~~any of claims 11 to 20~~ claim 11, wherein the amino acid labeling reagent is an amino acid fluorescence-labeling reagent.

22. (Original) The examination method of claim 21, wherein the amino acid fluorescence-labeling reagent is 4-fluoro-7-nitro-2,1,3-benzoxadiazole.

23. (Original) A reagent for examining schizophrenia, which comprises an amino acid labeling reagent.

24. (Original) The reagent of claim 23, wherein the amino acid labeling reagent is an amino acid fluorescence-labeling reagent.

25. (Original) The reagent of claim 24, wherein the amino acid fluorescence-labeling reagent is 4-fluoro-7-nitro-2,1,3-benzoxadiazole.

26. **(Original)** A method of examining or diagnosing schizophrenia, which comprises measuring concentrations of D-serine and L-serine in serum and using an increase or decrease in the concentration as an index.

27. **(Original)** A method of examining or diagnosing schizophrenia, which comprises measuring a D-serine concentration in serum and using a decrease in the concentration as an index.

28. **(Original)** A method of examining or diagnosing schizophrenia, which comprises measuring an L-serine concentration in serum and using an increase in the concentration as an index.